Ruthenium-106 brachytherapy and intravitreal bevacizumab for retinal capillary hemangioma

Vincenzo Russo, Andrea Stella, Antonio Barone, Ingrid Scott, Nicola Delle Noci

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The purpose of this study is to report a case of retinal capillary hemangioma treated with ruthenium-106 brachytherapy combined with intravitreal bevacizumab. A 58-year-old woman presented with blurred vision in her left eye for 15 days. Best-corrected visual acuity (BCVA) was counting fingers at 3 m in her left eye. Examination showed a peripheral endophytic retinal capillary hemangioma, with associated macular edema and diffuse hard exudates in a macular star pattern. B-scan ultrasonography revealed a solid, highly reflective retinal tumor measuring 7.1 × 7.5 mm in basal dimension and 3.5 mm in thickness. The hemangioma and macular edema were treated with ruthenium-106 brachytherapy (500 Gy) followed 1 month later with an intravitreal injection of 1.25 mg (0.05 ml) bevacizumab. After 10 months of follow-up, examination demonstrated involution of the hemangioma, resolution of the macular edema, less hard exudates, and improvement of BCVA to 20/25. Ruthenium-106 brachytherapy combined with intravitreal bevacizumab was associated with significant involution of the choroidal hemangioma with resolution of the macular edema and improvement in visual acuity.

Original languageEnglish (US)
Pages (from-to)71-75
Number of pages5
JournalInternational Ophthalmology
Volume32
Issue number1
DOIs
StatePublished - Feb 1 2012

Fingerprint

Capillary Hemangioma
Macular Edema
Ruthenium
Brachytherapy
Hemangioma
Visual Acuity
Exudates and Transudates
Retinal Neoplasms
Intravitreal Injections
Fingers
Ultrasonography
Bevacizumab

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

Russo, Vincenzo ; Stella, Andrea ; Barone, Antonio ; Scott, Ingrid ; Noci, Nicola Delle. / Ruthenium-106 brachytherapy and intravitreal bevacizumab for retinal capillary hemangioma. In: International Ophthalmology. 2012 ; Vol. 32, No. 1. pp. 71-75.
@article{67b5c5d35a8e4b818284459bcfb61b2e,
title = "Ruthenium-106 brachytherapy and intravitreal bevacizumab for retinal capillary hemangioma",
abstract = "The purpose of this study is to report a case of retinal capillary hemangioma treated with ruthenium-106 brachytherapy combined with intravitreal bevacizumab. A 58-year-old woman presented with blurred vision in her left eye for 15 days. Best-corrected visual acuity (BCVA) was counting fingers at 3 m in her left eye. Examination showed a peripheral endophytic retinal capillary hemangioma, with associated macular edema and diffuse hard exudates in a macular star pattern. B-scan ultrasonography revealed a solid, highly reflective retinal tumor measuring 7.1 × 7.5 mm in basal dimension and 3.5 mm in thickness. The hemangioma and macular edema were treated with ruthenium-106 brachytherapy (500 Gy) followed 1 month later with an intravitreal injection of 1.25 mg (0.05 ml) bevacizumab. After 10 months of follow-up, examination demonstrated involution of the hemangioma, resolution of the macular edema, less hard exudates, and improvement of BCVA to 20/25. Ruthenium-106 brachytherapy combined with intravitreal bevacizumab was associated with significant involution of the choroidal hemangioma with resolution of the macular edema and improvement in visual acuity.",
author = "Vincenzo Russo and Andrea Stella and Antonio Barone and Ingrid Scott and Noci, {Nicola Delle}",
year = "2012",
month = "2",
day = "1",
doi = "10.1007/s10792-011-9513-1",
language = "English (US)",
volume = "32",
pages = "71--75",
journal = "International Ophthalmology",
issn = "0165-5701",
publisher = "Springer Netherlands",
number = "1",

}

Ruthenium-106 brachytherapy and intravitreal bevacizumab for retinal capillary hemangioma. / Russo, Vincenzo; Stella, Andrea; Barone, Antonio; Scott, Ingrid; Noci, Nicola Delle.

In: International Ophthalmology, Vol. 32, No. 1, 01.02.2012, p. 71-75.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Ruthenium-106 brachytherapy and intravitreal bevacizumab for retinal capillary hemangioma

AU - Russo, Vincenzo

AU - Stella, Andrea

AU - Barone, Antonio

AU - Scott, Ingrid

AU - Noci, Nicola Delle

PY - 2012/2/1

Y1 - 2012/2/1

N2 - The purpose of this study is to report a case of retinal capillary hemangioma treated with ruthenium-106 brachytherapy combined with intravitreal bevacizumab. A 58-year-old woman presented with blurred vision in her left eye for 15 days. Best-corrected visual acuity (BCVA) was counting fingers at 3 m in her left eye. Examination showed a peripheral endophytic retinal capillary hemangioma, with associated macular edema and diffuse hard exudates in a macular star pattern. B-scan ultrasonography revealed a solid, highly reflective retinal tumor measuring 7.1 × 7.5 mm in basal dimension and 3.5 mm in thickness. The hemangioma and macular edema were treated with ruthenium-106 brachytherapy (500 Gy) followed 1 month later with an intravitreal injection of 1.25 mg (0.05 ml) bevacizumab. After 10 months of follow-up, examination demonstrated involution of the hemangioma, resolution of the macular edema, less hard exudates, and improvement of BCVA to 20/25. Ruthenium-106 brachytherapy combined with intravitreal bevacizumab was associated with significant involution of the choroidal hemangioma with resolution of the macular edema and improvement in visual acuity.

AB - The purpose of this study is to report a case of retinal capillary hemangioma treated with ruthenium-106 brachytherapy combined with intravitreal bevacizumab. A 58-year-old woman presented with blurred vision in her left eye for 15 days. Best-corrected visual acuity (BCVA) was counting fingers at 3 m in her left eye. Examination showed a peripheral endophytic retinal capillary hemangioma, with associated macular edema and diffuse hard exudates in a macular star pattern. B-scan ultrasonography revealed a solid, highly reflective retinal tumor measuring 7.1 × 7.5 mm in basal dimension and 3.5 mm in thickness. The hemangioma and macular edema were treated with ruthenium-106 brachytherapy (500 Gy) followed 1 month later with an intravitreal injection of 1.25 mg (0.05 ml) bevacizumab. After 10 months of follow-up, examination demonstrated involution of the hemangioma, resolution of the macular edema, less hard exudates, and improvement of BCVA to 20/25. Ruthenium-106 brachytherapy combined with intravitreal bevacizumab was associated with significant involution of the choroidal hemangioma with resolution of the macular edema and improvement in visual acuity.

UR - http://www.scopus.com/inward/record.url?scp=84857607373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857607373&partnerID=8YFLogxK

U2 - 10.1007/s10792-011-9513-1

DO - 10.1007/s10792-011-9513-1

M3 - Article

C2 - 22271068

AN - SCOPUS:84857607373

VL - 32

SP - 71

EP - 75

JO - International Ophthalmology

JF - International Ophthalmology

SN - 0165-5701

IS - 1

ER -